The U.S. Supreme Court dashed the last hopes of W.L. Gore & Assoc. in its long-running patent war with C.R. Bard (NYSE:BCR) over vascular graft technology.
W.L. Gore & Associates
Weight loss: GI Dynamics, W.L. Gore settle patent beef
A long-running dispute between W.L Gore & Associates and GI Dynamics (ASX:GID) is over after the medical device companies agreed to settle the beef.
Gore lands CE Mark for its next-gen endoprosthesis
Endotach sues Medtronic over stent graft patents
Medtronic (NYSE:MDT) infringes a pair of patents licensed to Endotach LLC with 3 of its stent grafts for treating abdominal aortic aneurysms, according to a lawsuit filed by Endotach against the medtech titan.
The Frisco, Texas-based company holds the exclusive license to the duo of patents from their inventor’s widow, according to court documents.
Gore defends PFO closure devices in the aftermath of the St. Jude RESPECT trial
W.L. Gore appeals to Supreme Court over $186M loss to C.R. Bard
The U.S. Supreme Court dashed the last hopes of W.L. Gore & Assoc. its long-running patent war with C.R. Bard (NYSE:BCR) over vascular graft technology.
Gore lands FDA approval to add next-gen septal occluder to Reduce study
W.L. Gore & Associates today announced that it had won FDA approval to adds its next-generation GORE Septal Occluder to its Reduce clinical study, which is already evaluating its older Helex septal occluder in prevention of recurrent stroke in patients with patent foramen ovale, a hole between the upper chambers of the heart.
Gore enrolls 1st patient in next-gen transcatheter septal occluder trial
W.L. Gore & Associates today announced successful launch of its GORE Septal Occluder Clinical trial, enrolling the 1st of 50 patients to evaluate the company’s heart implant in treatment of atrial septal defect.
The new catheter-based septal occluder is a permanent implant designed to treat holes in the septum between the chambers of the heart.
Gore touts CE Mark win for Hybrid Vascular Graft
W.L. Gore & Associates touted CE Mark approval in the European Union for its Gore Hybrid Vascular Graft.
The device, which won FDA clearance in 2010, is indicated for use as replacement or bypass of diseased blood vessels while addressing common causes of graft failure.
The graft is a vascular prosthesis designed to expand treatment options for blood outflow by working in the maximum number of sites available.
Angioplasty balloon maker wins FDA approval | Regulatory Roundup
Angioplasty balloon maker r4 Technologies wins FDA approval
Maple Grove, Minn.-based r4 Technologies landed FDA approval for its Vector percutaneous transluminal angioplasty balloon catheters, which come in 28 different sizes.
MassDevice.com +7 | The top 7 med-tech stories for the week of June 22, 2012
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.